Literature DB >> 3014247

Role of ADH in ethylketocyclazocine-induced diuresis: studies in the Brattleboro rat.

G R Slizgi, J H Ludens.   

Abstract

Kappa opioids produce diuresis presumably through ADH. We investigated further the role of ADH in kappa-induced diuresis by utilizing the Brattleboro rat, a strain lacking endogenous ADH. Ethylketocyclazocine (EKC), a kappa opioid prototype, increased urine formation in Sprague-Dawley, but not in Brattleboro rats. Furthermore, EKC pretreatment abolished the antidiuretic response to ADH administered exogenously to Brattleboro rats. Our study suggests that, in addition to a fall in plasma ADH reported previously, kappa opioids have direct effects on the renal response to ADH.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014247     DOI: 10.1016/0024-3205(86)90613-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man.

Authors:  H J Kramer; W Uhl; B Ladstetter; A Bäcker
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

2.  Mechanism of diuretic action of spiradoline (U-62066E)--a kappa opioid receptor agonist in the human.

Authors:  G H Rimoy; N K Bhaskar; D M Wright; P C Rubin
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

3.  Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A.

Authors:  S Inan; D Y-W Lee; L Y Liu-Chen; A Cowan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-17       Impact factor: 3.000

4.  Renal responses produced by microinjection of the kappa opioid receptor agonist, U50-488H, into sites within the rat lamina terminalis.

Authors:  Cynthia Franklin; Lourdes Fortepiani; Tin Nguyen; Yolanda Rangel; Randy Strong; Helmut B Gottlieb
Journal:  Pharmacol Res Perspect       Date:  2015-02-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.